论文部分内容阅读
对慢性乙型肝炎50例,慢性丙型肝炎20例,应用胸腺肽α1和干扰素α1b。联合治疗6个月,治疗后其PCR-HBV-DNA的阴转率为68.0％(3/50),PCR-HCV-RNA的阴转率为70.0％(14/20),较对照组(干扰素。α1b)的PCR-HBV-DNA的阴转率44.0％(25/50)、PCR-HCV-RNA的阴转率30.0％(6/20)为高,P<0.05。通过治疗前、后检测T细胞亚群、sIL-2R及TNFα发现,治疗前CD_8~+(35.3±6.65％/27.1±4.28％),sIL-2R(820±141.9ng/ml/250±59.64u/ml),和TNFα(6.8±1.14ng/ml/2.55±0.38ng/ml)明显增高,经胸腺肽处理后,CD_8~+(28.3±4.85％)、sIL-2R(378±86.81mg/ml)和TNFα(3.94±0.53ng/ml)均明显下降,相反CD_4~1(38.6±4.90％)相应增高,P<0.01。说明胸腺肽通过调整T细胞活性,促进CD_4~+成熟提高了干扰素的抗病毒疗效。
50 cases of chronic hepatitis B, chronic hepatitis C in 20 cases, the application of thymosin α1 and interferon α1b. After treatment for 6 months, the negative conversion rate of PCR-HBV-DNA was 68.0% (3/50) and the negative conversion rate of PCR-HCV-RNA was 70.0% (14/20) The negative conversion rate of PCR-HCV-RNA was 30.0% (6/20) in PCR-HCV-RNA, and the negative conversion rate of PCR-HBV-RNA was 44.0% (25/50) The levels of CD_8 ~ + (35.3 ± 6.65% / 27.1 ± 4.28%), sIL-2R (820 ± 141.9ng / ml / 250 ± 59.64u (28.3 ± 4.85%), sIL-2R (378 ± 86.81mg / ml) and TNFα (6.8 ± 1.14ng / ml / 2.55 ± 0.38ng / ml) And TNFα (3.94 ± 0.53ng / ml) were significantly decreased, while CD_4 ~ 1 (38.6 ± 4.90%) correspondingly increased, P <0.01. It shows that thymosin improves the antiviral effect of interferon by regulating T cell activity and promoting CD 4 + maturation.